|
Title |
Imipramine versus escitalopram in generalized anxiety disorder
|
|
Authors |
Yogesh Jain 1,*, Abhishek Mishra 2, Pawan Kumar Maurya 3, Hemlata Verma 4, Santenna Chenchula 1,* & Jay Prakash Agarwal 5
|
|
Affiliation |
1Department of Pharmacology, Chirayu Medical College and Hospital, Bhopal, Madhya Pradesh, India; 2Department of Pharmacology, People's College of Medical Sciences and Research Centre, Bhopal, Madhya Pradesh, India; 3Department of Pharmacology, Shyam Shah Medical College (SSMC), Rewa, Madhya Pradesh, India; 4Department of Pharmacology, Gandhi Medical College, Bhopal, Madhya Pradesh, India; 5Department of Psychiatry, Gandhi Medical College, Bhopal, Madhya Pradesh, India; *Corresponding author
|
|
|
Yogesh Jain - E-mail: pharmalove69@gmail.com |
|
Article Type |
Research Article
|
|
Date |
Received October 1, 2026; Revised October 31, 2026; Accepted October 31, 2026, Published October 31, 2026
|
|
Abstract |
Generalized anxiety disorder (GAD) is a common, chronic condition, and real-world comparative data on imipramine and escitalopram are limited. Therefore, it is of interest to compare their effectiveness and safety in outpatients with newly diagnosed GAD over 24 weeks. In this prospective observational study at Gandhi Medical College and Hamidia Hospital, Bhopal, 100 patients received imipramine (n=50) or escitalopram (n=50) at the treating physician's discretion. Anxiety was assessed with the Hamilton Anxiety Rating Scale (HAM-A) at baseline and at weeks 4, 12 and 24, and adverse drug reactions were recorded. Mean HAM-A score fell from 35.05 to 9.42 (73.1%) with imipramine and from 36.08 to 8.95 (75.2%) with escitalopram. Drowsiness was significantly more frequent with imipramine (36% vs 2%; P<0.001). Thus, both drugs produced comparable, substantial reductions in anxiety, with better tolerability for escitalopram; randomized trials are warranted. |
|
Keywords |
Generalized anxiety disorder (GAD), imipramine, escitalopram, hamilton anxiety rating scale, tricyclic antidepressant, selective serotonin reuptake inhibitor
|
|
Citation |
Jain et al. Bioinformation 22(10): 6559-6564 (2026)
|
|
Edited by |
P Kangueane
|
|
ISSN |
0973-2063
|
|
Publisher |
|
|
License |
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
|
|
|
|